Literature DB >> 3094186

Hepatic steatosis in total parenteral nutrition: failure of fatty infiltration to correlate with abnormal serum hepatic enzyme levels.

H C Sax, M A Talamini, K Brackett, J E Fischer.   

Abstract

Total parenteral nutrition (TPN) is associated with hepatic biochemical and morphologic changes. Suggested causes include excessive glucose calories, fatty acid deficiency, and enterically derived hepatotoxins escaping atrophied bowel. Male Sprague-Dawley rats were cannulated or sham operated with internal jugular ligation. The cannulated groups received TPN with a 25% dextrose base, or TPN 12.5% dextrose and given nothing by mouth, or saline solution and allowed to eat ad lib. Sham animals ate ad lib. After 6 days the animals were killed and portal blood was assayed for endotoxin and cultured. Cultures were also taken of the liver. Serum hepatic enzyme concentration and hepatic fat were determined. All cultures and endotoxin assays were negative. Microscopy revealed nonlipid vacuolization in both TPN groups, a finding reproduced by direct portal infusion of endotoxin. There was significant hepatic steatosis in the 25% dextrose base TPN versus all other groups (28.6% liver weight versus 6.3% liver weight; p less than 0.05). This was correlated with caloric intake (28.7 calories/100 gm/day versus 21.2 calories/100 gm/day; p less than 0.05). Liver enzymes were not significantly different among groups. We conclude that hepatic steatosis in TPN is a result of overfeeding a glucose only substrate and that fatty infiltration is independent of changes in blood hepatic enzyme concentrations. Although other morphologic changes of hepatotoxin-induced injury were seen in the TPN group, portal endotoxemia to the level of 1 ng/ml could not be documented.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094186

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

Review 1.  Complications of long-term home total parenteral nutrition: their identification, prevention and treatment.

Authors:  A L Buchman
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

Review 2.  Specific topics and complications of parenteral nutrition.

Authors:  Eduardo E Montalvo-Jave; José L Zarraga; Michael G Sarr
Journal:  Langenbecks Arch Surg       Date:  2007-01-13       Impact factor: 3.445

3.  A defect in the activities of Δ and Δ desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease.

Authors:  Undurti N Das
Journal:  World J Diabetes       Date:  2011-11-15

4.  The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome.

Authors:  Shun Onishi; Tatsuru Kaji; Waka Yamada; Kazuhiko Nakame; Tomoe Moriguchi; Koushirou Sugita; Koji Yamada; Takafumi Kawano; Motoi Mukai; Masakazu Souda; Sohsuke Yamada; Takako Yoshioka; Akihide Tanimoto; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2016-09-20       Impact factor: 1.827

5.  Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis.

Authors:  Armando Guerra Ruiz; Fernando Casafont; Javier Crespo; Amalia Cayón; Marta Mayorga; Angel Estebanez; José Carlos Fernadez-Escalante; Fernando Pons-Romero
Journal:  Obes Surg       Date:  2007-10       Impact factor: 4.129

6.  Manganese in human parenteral nutrition: considerations for toxicity and biomonitoring.

Authors:  Dinamene Santos; Camila Batoreu; Luisa Mateus; A P Marreilha Dos Santos; Michael Aschner
Journal:  Neurotoxicology       Date:  2013-11-01       Impact factor: 4.294

7.  Liver dysfunction associated with artificial nutrition in critically ill patients.

Authors:  Teodoro Grau; Alfonso Bonet; Mercedes Rubio; Dolores Mateo; Mercé Farré; José Antonio Acosta; Antonio Blesa; Juan Carlos Montejo; Abelardo García de Lorenzo; Alfonso Mesejo
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.